Evidence mapPaperPMID 40120008Full record

ReviewDiscover oncology2025

Unveiling the future of cancer stem cell therapy: a narrative exploration of emerging innovations.

Joseph Nhyira Obisi, Abike Ndidiamaka Josephine Abimbola, Oluwasegun Adesina Babaleye, Peter Kwame Atidoglo, Saviour God'swealth Usin, Eudora Obioma Nwanaforo, Faith Sutu Patrick-Inezi, Ilemobayo Victor Fasogbon, Joseph Chimezie, Christianah Adebimpe Dare and 3 more

Abstract readReview
In one paragraph

Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Epitranscriptomic alterations induced by environmental toxins: implications for RNA modifications and disease.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2025
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Joseph Nhyira ObisiKwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Abike Ndidiamaka Josephine AbimbolaDepartment of Environmental Chemistry, University of Ibadan, Ibadan, Nigeria.
Oluwasegun Adesina BabaleyeCenter for Human Virology and Genomics, Department of Microbiology, Nigerian Institute of Medical Research, Lagos, Nigeria.
Peter Kwame AtidogloDepartment of Biomedical Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana.
Saviour God'swealth UsinCancer Research and Molecular Biology Laboratory, Department of Biochemistry, College of Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria.
Eudora Obioma NwanaforoEnvironmental Health Science Department, School of Heath Technology, Federal University of Technology Owerri, Owerri, Nigeria.
Faith Sutu Patrick-IneziEbonyi State University, Abakaliki, Nigeria.
Ilemobayo Victor FasogbonDepartment of Biochemistry, Kamapla International University, Osogbo, Uganda.
Joseph ChimezieDepartment of Physiology, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Christianah Adebimpe DareDepartment of Biochemistry, Osun State University, Osogbo, Nigeria.
Oluwadoyinsayemi Oluwadamilare KutiSchool of Physical Sciences, Department of Statistics, Federal University of Technology, Akure, Ondo-State, Nigeria.
Daniel Ejim UtiDepartment of Biochemistry/Research and Publications, Kampala International University, P.O. Box 20000, Kampala, Uganda. daniel.ejimuti@kiu.ac.ug.
Humphrey Chukwudi OmeogaDepartment of Biological Sciences, State University of New York, Albany, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer stem cells (CSCs), are a critical subpopulation within tumours, and are defined by their capacity for self-renewal, differentiation, and tumour initiation. These unique traits contribute to tumour progression, metastasis, and resistance to conventional treatments like chemotherapy and radiotherapy, often resulting in cancer recurrence and poor patient outcomes. As such, CSCs have become focal points in developing advanced cancer therapies. This review highlights progress in CSC-targeted treatments, including chimeric antigen receptor T-cell (CAR-T) therapy, immunotherapy, molecular targeting, and nanoparticle-based drug delivery systems. Plant-derived compounds and gene-editing technologies, such as clustered regularly interspaced short palindromic repeats (CRISPR), are explored for their potential to enhance precision and minimize side effects. Metabolic pathways integral to CSC survival, such as mitochondrial dynamics, mitophagy (regulated by dynamin-related protein 1 [DRP1] and the PINK1/Parkin pathway), one-carbon metabolism, amino acid metabolism (involving enzymes like glutaminase (GLS) and glutamate dehydrogenase (GDH]), lipid metabolism, and hypoxia-induced metabolic reprogramming mediated by hypoxia-inducible factors (HIF-1α and HIF-2α), are examined as therapeutic targets. The adaptability of CSCs through autophagy, metabolic flexibility, and epigenetic regulation by metabolites like α-ketoglutarate, succinate, and fumarate is discussed. Additionally, extracellular vesicles and nicotinamide adenine dinucleotide (NAD⁺) metabolism are identified as pivotal in redox balance, DNA repair, and epigenetic modifications. Addressing challenges such as tumour heterogeneity, immune evasion, and treatment durability requires interdisciplinary collaboration. Advancing CSC-targeted therapies is essential for overcoming drug resistance and preventing cancer relapse, paving the way for transformative cancer treatments. This review underscores the importance of leveraging innovative technologies and fostering collaboration to revolutionize cancer treatment.

Indexed as

Cancer stem cells (CSCs)CAR T-cell therapyChemotherapeutic drug resistanceGene editing methodsNanoparticular drug deliveryTumour initiation and progression

Identifiers

PMID40120008
PMCPMC11929669

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.